Sodium orthovanadate suppresses DNA damage-induced caspase activation and apoptosis by inactivating p53

Cell Death and Differentiation

Volumn 13, Issue 3, 2006, Pages 499-511

  Morita, A ^a   Zhu, J ^a   Suzuki, N ^a,b   Enomoto, A ^a,c   Matsumoto, Y ^a,c   Tomita, M ^a   Suzuki, T ^c   Ohtomo, K ^a,c   Hosoi, Y ^a,c  

^a UNIVERSITY OF TOKYO   (Japan)

^b INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Apoptosis; Caspase; DNA damage; p53; Sodium orthovanadate

Indexed keywords

CASPASE; CISPLATIN; DEXAMETHASONE; DNA; PROTEIN BAX; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE; STAUROSPORINE; VANADATE SODIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DNA BINDING; DNA DAMAGE; DNA FLANKING REGION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REPRESSION; GEL MOBILITY SHIFT ASSAY; IN VITRO STUDY; IN VIVO STUDY; MALE; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASES; CELL LINE, TUMOR; DNA DAMAGE; ENZYME ACTIVATION; HUMANS; MEMBRANE POTENTIALS; MITOCHONDRIA; TUMOR SUPPRESSOR PROTEIN P53; VANADATES;

ANIMALIA;

EID: 33645163703     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401768     Document Type: Article

References (40)

1. Nakano H, Kohara M and Shinohara K (2001) Evaluation of the relative contribution of p53-mediated pathway in X-ray-induced apoptosis in human leukemic MOLT-4 cells by transfection with a mutant p53 gene at different expression levels. Cell Tissue Res. 306: 101-106
2. Enomoto A, Suzuki N, Hirano K, Matsumoto Y, Morita A, Sakai K and Koyama H (2000) Involvement of SAPK/JNK pathway in X-ray-induced rapid cell death of human T-cell leukemia cell line MOLT-4. Cancer Lett. 155: 137-144
3. Enomoto A, Suzuki N, Kang Y, Hirano K, Matsumoto Y, Zhu J, Morita A, Hosoi Y, Sakai K and Koyama H (2003) Decreased c-Myc expression and its involvement in X-ray-induced apoptotic cell death of human T-cell leukemia cell line MOLT-4. Int. J. Radiat. Biol. 79: 589-600
4. Morita A, Suzuki N, Matsumoto Y, Hirano K, Enomoto A, Zhu J and Sakai K (2000) p41 as a possible marker for cell death is generated by caspase cleavage of p42/SETβ in irradiated MOLT-4 cells. Biochem. Biophys. Res. Commun. 278: 627-632
5. Morimatsu A, Suzuki N, Hirano K, Matsumoto Y and Sakai K (1996) Identification and characterization of a protein found after X-irradiation in human T cell leukemia. J. Radiat. Res. 37: 1-11
6. Hengartner MO (2000) The biochemistry of apoptosis. Nature 407: 770-776
7. Zheng TS, Hunot S, Kuida K and Flavell RA (1999) Caspase knockouts: matters of life and death. Cell Death Differ. 6: 1043-1053
8. Roucou X and Martinou JC (2001) Conformational change of Bax: A question of life or death. Cell Death Differ. 8: 875-877
9. Desagher S, Osen-Sand A, Nichols A, Eskes R, Montessuit S, Lauper S, Maundrell K, Antonsson B and Martinou JC (1999) Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J. Cell Biol. 144: 891-901
10. Wahl GM and Carr AM (2001) The evolution of diverse biological responses to DNA damage: Insights from yeast and p53. Nature Cell Biol. 3: E277-E286
11. Villunger A, Michalak EM, Coultas L, Mullauer F, Bock G, Ausserlechner MJ, Adams JM and Strasser A (2003) p53- and drug-induced apoptotic responses mediated by BH3-only proteins Puma and Noxa. Science 302: 1036-1038
12. Konishi A, Shimizu S, Hirota J, Takao T, Fan Y, Matsuoka Y, Zhang L, Yoneda Y, Fujii Y, Skoultchi AI and Tsujimoto Y (2003) Involvement of Histone H1.2 in apoptosis induced by DNA double-strand breaks. Cell 114: 673-688
13. Gordon JA (1991) Use of vanadate as protein-phosphotyrosine phosphatase inhibitor. Methods Enzymol. 201: 477-482
14. Cuncic C, Desmarais S, Detich N, Tracey AS, Gresser MJ and Ramachandran C (1999) Bis(N,N-dimethylhydroxamido)hydrooxovanadate inhibition of protein tyrosine phosphatase activity in intact cells: Comparison with vanadate. Biochem. Pharmacol. 58: 1859-1867
15. Fujiwara S, Watanabe T, Nagatsu T, Gohda J, Imoto M and Umezawa K (1997) Enhancement or induction of neurite formation by a protein tyrosine phosphatase inhibitor, 3,4-Dephostatin, in growth factor-treated PC12h cells. Biochem. Biophys. Res. Commun. 238: 213-217
16. Pasquet JM, Dachary-Prigent J and Nurden AT (1998) Microvesicle release is associated with extensive protein tyrosine dephosphorylation in platelets stimulated by A23187 or a mixture of thrombin and collagen. Biochem. J. 333: 591-599
17. Saito Y, Mitsuhashi N, Sakurai H, Ishikawa H, Hasegawa M, Akimoto T, Hayakawa K and Niibe H (1999) Apoptosis and appearance of Trp53-positive micronuclei in murine tumors with different radioresponses in vivo. Radiat. Res. 152: 462-467
18. Mathieu AL, Gonin S, Leverrier Y, Blanquier B, Thomas J, Dantin C, Martin G, Baverel G and Marvel J (2001) Activation of the phosphatidylinositol 3-kinase/Akt pathway protects against interleukin-3 starvation but not DNA damage-induced apoptosis. J. Biol. Chem. 276: 10935-10942
19. Shimizu T and Pommier Y (1997) Camptothecin-induced apoptosis in p53-null human leukemia HL60 cells and their isolated nuclei: Effects of the protease inhibitors Z-VAD-fmk and dichloroisocoumarin suggest an involvement of both caspases and serine proteases. Leukemia 11: 1238-1244
20. Sugimoto K, Toyoshima H, Sakai R, Miyagawa K, Hagiwara K, Ishikawa F, Takaku F, Yazaki Y and Hirai H (1992) Frequent mutations in the p53 gene in human myeloid leukemia cell lines. Blood 79: 2378-2383
21. Harris N, Brill E, Shohat O, Prokocimer M, Wolf D, Arai N and Rotter V (1986) Molecular basis for heterogeneity of the human p53 protein. Mol. Cell. Biol. 6: 4650-4656
22. Landesman Y, Bringold F and Kimchi A (1994) p53 undergoes epitopic changes in vitro by sodium-vanadate. Oncogene 9: 1241-1245
23. Kernohan NM, Hupp TR and Lane DP (1996) Modification of an N-terminal regulatory domain of T antigen restores p53-T antigen complex formation in the absence of an essential metal ion cofactor. J. Biol. Chem. 271: 4954-4960
24. Meplan C, Mann K and Hainaut P (1999) Cadmium induces conformational modifications of wild-type p53 and suppresses p53 response to DNA damage in cultured cells. J. Biol. Chem. 274: 31663-31670
25. Baliga B and Kumar S (2003) Apaf-1/cytochrome c apoptosome: An essential initiator of caspase activation or just a sideshow? Cell Death Differ. 10: 16-18
26. Lawson AE, Bao H, Wickrema A, Jacobs-Helber SM and Sawyer ST (2000) Phosphatase inhibition promotes antiapoptotic but not proliferative signaling pathways in erythropoietin-dependent HCD57 cells. Blood 96: 2084-2092
27. Chin LS, Murray SF, Harter DH, Doherty PF and Singh SK (1999) Sodium vanadate inhibits apoptosis in malignant glioma cells: A role for Akt/ PKB. J. Biomed. Sci. 6: 213-218
28. Gamero AM and Larner AC (2001) Vanadate facilitates interferon α-mediated apoptosis that is dependent on the Jak/Stat pathway. J. Biol. Chem. 276: 13547-13553
29. Stewart CE, Mihai R and Holly JM (1999) Increased tyrosine kinase activity but not calcium mobilization is required for ceramide-induced apoptosis. Exp. Cell Res. 250: 329-338
30. Guo YL, Baysal K, Kang B, Yang LJ and Williamson JR (1998) Correlation between sustained c-Jun N-terminal protein kinase activation and apoptosis induced by tumor necrosis factor- in rat mesangial cells. J. Biol. Chem. 273: 4027-4034
31. Figiel I and Kaczmarek L (1997) Orthovanadate induces cell death in rat dentate gyrus primary culture. Neuroreport 8: 2465-2470
32. Cip1. Mol. Cell 11: 1491-1501
33. Meplan C, Verhaegh G, Richard MJ and Hainaut P (1999) Metal ions as regulators of the conformation and function of the tumour suppressor protein p53: Implications for carcinogenesis. Proc. Nutr. Soc. 58: 565-571
34. 1 Mice. Toxicol. Sci. 74: 287-296
35. Sakai A (1997) Orthovanadate, an inhibitor of protein tyrosine phosphatases, acts more potently as a promoter than as an initiator in the BALB/3T3 cell transformation. Carcinogenesis 18: 1395-1399
36. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr CA, Butel JS and Bradley A (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-221
37. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV and Gudkov AV (1999) A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285: 1733-1737
38. Chernov MV and Stark GR (1997) The p53 activation and apoptosis induced by DNA damage are reversibly inhibited by salicylate. Oncogene 14: 2503-2510
39. Sakata K, Matsumoto Y, Tauchi H, Satoh M, Oouchi A, Nagakura H, Koito K, Hosoi Y, Suzuki N, Komatsu K and Hareyama M (2001) Expression of genes involved in repair of DNA double-strand breaks in normal and tumor tissues. Int. J. Radiat. Oncol. Biol. Phys. 49: 161-167
40. Komiyama S, Taniguchi S, Matsumoto Y, Tsunoda E, Ohto T, Suzuki Y, Yin HL, Tomita M, Enomoto A, Morita A, Suzuki T, Ohtomo K, Hosoi Y and Suzuki N (2004) Potentiality of DNA-dependent protein kinase to phosphorylate Ser46 of human p53. Biochem. Biophys. Res. Commun. 323: 816-822